Search Results

A2 Biotherapeutics, Inc. today announced dosing of the first patient in the Phase 1 clinical trial of A2B694.

A2 Biotherapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to A2B530 for the treatment of germline heterozygous HLA-A*02(+) patients with colorectal cancer that expresses carcinoembryonic antigen (CEA) and has lost HLA-A*02 expression.

A2 Biotherapeutics, Inc. will present updates on three ongoing clinical trials in poster presentations during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

A2 Biotherapeutics, Inc. today announced the appointment of James Robinson as its Chief Executive Officer and a member of its Board of Directors, effective April 1st , 2024.

Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”), (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the first Phase 1b/2a clinical trial of SON-080 was cleared to proceed to Phase 2 after review by the independent DSMB.

A2 Biotherapeutics, Inc. (A2 Bio) a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to selectively target tumor cells and protect normal cells, today announced the acceptance of three posters for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting May 31-June 4, 2024, in Chicago, Ill.